ArticleClinical case reports2026
Solid Subtype of Papillary Thyroid Carcinoma: A Case Series Highlighting Aggressive Features.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm. Its solid/trabecular subtype (STPTC) is rare, and its aggressiveness remains controversial. We describe the clinical, histopathological, and immunohistochemical characteristics of three STPTC cases, highlighting their biological behavior and impact on current classification. Two patients exhibited aggressive clinical courses with extensive lymphatic metastases and possible distant spread, while the third case showed a more indolent progression. Immunohistochemistry revealed positivity for cytokeratin 7, cytokeratin 19, thyroglobulin, TTF-1, and PAX8, with negativity for CD56, synaptophysin, and p63, among others. Although the 2022 WHO classification does not consider STPTC an aggressive subtype, the literature and our findings suggest reconsideration. Immunohistochemistry and the Ki-67 proliferation index may be key tools for differential diagnosis and prognosis. STPTC can exhibit aggressive behavior, particularly in young patients. Early diagnosis and individualized therapeutic approaches are essential to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.